Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer.
Pembrolizumab, when use in combination with pemetrexed and platinum chemotherapy, is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase positive mutations. It is only recommended if:
- Pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses
- MSD provides pembrolizumab according to the managed access agreement
